GTC Biotherapeutics (fka GTCB)

[croumagnon]

"is not related to bias or part of a conspiracy, but results from the historical method of how a drug gets through to the market, and is inadvertently aided by the FDA rule which declares a biotherapeutic's method of production, is a integral part of its identity."

Your point is well understood Jesse but, up till recently, the consensus on this board was that FOBs will be the future bonanza for GTCB. If your contention is correct, in that transgenics will not be able to enter the FOB arena without running new trials, then all our previous excitement was not justified...

I hope Dew can chime in on this conversation...